Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of Defense to support Phase 3-focused work advancing its lead bacteriophage program, AP-SA02, in complicated Staphylococcus aureus bacteremia. The latest award follows $28.7 million previously provided under the funding arrangement, bringing cumulative Department of Defense support to approximately $32.4 million. Armata shares were down 10.95% at $3.74 at the time of publication Wednesday. The stock remained below its 20-day, 50-day, 100-day and 200-day simple moving averages, while a negative MACD reading pointed to weak momentum. The 20-day average remained above the 50-day average, but the 50-day average was below the 200-day average following a July Death Cross, leaving the longer-term technical backdrop bearish. Traders were watching $4.74, aligned with the 20-day exponential moving average, as a potential first resistance level, and $2.94 as support near the 52-week low. Armata's Benzinga Edge momentum score was 9.15, classified as weak.